


In the claims:

1. (Currently Amended) A compound of formula (I)



X is  $\text{CH}_2$ ;

$\text{R}^1$  is an optionally substituted aryl;

$\text{R}^2$  is carboxy;

$\text{R}^3$  is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl;

$\text{R}^4$  is a group  $\text{NHSO}_2\text{R}^{15}$  where  $\text{R}^{15}$  is optionally substituted alkyl or optionally substituted aryl;

$\text{R}^5$ ,  $\text{R}^6$  and  $\text{R}^7$  are independently selected from hydrogen or an optionally substituted hydrocarbyl group.

2. (Currently Amended) A compound according to claim 1 wherein a group  $\text{R}^{15}$  as it appears in the definition of  $\text{R}^4$ , is substituted by at least one functional group, or an aryl or heterocyclyl group, either of which may themselves be substituted by one or more functional groups or further aryl or heterocyclyl groups.

3. (Currently Amended) A compound according to claim 1 wherein  $\text{R}^{15}$  is a substituted alkyl group or an optionally substituted heterocyclyl or optionally substituted phenyl group.

4. (Currently Amended) A compound according to claim 3 wherein  $\text{R}^{15}$  is alkyl substituted by a group of formula  $\text{NR}^{19}\text{R}^{20}$  where  $\text{R}^{19}$  and  $\text{R}^{20}$  are independently selected from hydrogen or optionally substituted hydrocarbyl, or  $\text{R}^{19}$  and  $\text{R}^{20}$  together form an optionally substituted ring.


~~which optionally contains further heteroatoms such as S(O)<sub>m</sub>, oxygen and nitrogen, n is an integer of 1 or 2, and m is 1 or 2.~~

5. (Cancelled)

6. (Previously Presented) A compound according to claim 1 wherein R<sup>1</sup> is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

7. (Cancelled)

8. (Previously Presented) A process for preparing a compound according to claim 1, which process comprises reacting a compound of formula (VII)



(VII)

where X, R<sup>1</sup>, R<sup>3</sup>, R<sup>5</sup>, R<sup>6</sup> and R<sup>7</sup> are as defined in claim 1, and R<sup>2</sup> is a group R<sup>2</sup> as defined in relation to formula (I) or a protected form thereof, with a compound of formula (VIII)



(VIII)

where Z is a leaving group and R<sup>22</sup> is a group SO<sub>2</sub>R<sup>15</sup>, where R<sup>15</sup> is group R<sup>15</sup> as defined in relation to formula (I) or a precursor thereof and thereafter if desired or necessary:

- (i) converting a precursor group R<sup>15</sup> to a group R<sup>15</sup> and/or converting a group R<sup>15</sup> to a different group R<sup>15</sup>; and
- (ii) deprotecting a group R<sup>2</sup> to a group R<sup>2</sup>.

9. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.

10. (Cancelled)

11. (Previously Presented) A method for treating inflammation in a warm blooded animal in need of such treatment comprising administering to said animal an effective amount of a compound according to claim 1, a pharmaceutically acceptable salt, or an *in vivo* hydrolysable ester thereof.